BACKGROUND AND AIM: Using of safety blood products did not stop improving these last years. The use of effective methods as well immunologicals as virologicals ones really reduces risk associated to blood transfusion. However, it persists residual risk (RR) of transfusion transmitted viral diseases. The aim of our study was to detect cases of seroconversion for HIV,and HBV among donors in the Senegalese national blood bank. And then, we estimated the RR of these virus. METHODS: We led a transverse retrospective study from 2003 (January 1st) to 2005 (December 31st). Had been included donors with at least two donations of blood during the period of study. They had to be seronegative for HIV and HBV after the first donation. All donors with only one donation had been excluded. RR was estimated by multiplying incidence rates by the durations of the window periods. RESULTS: During 3 years, we collected 425,503 donations; 388 were positive for HIV and 4240 for HBV. But we noted only two cases of seroconversion for HIV and 23 for HBV. So, RR estimated was 3,5 in 100,000 donation for HIV and 102,45 in 100,000 donations for VHB. CONCLUSION: It emerges from this study that the risk of blood transmitted virus is always high. Introduction of more sensitive tests (as nucleic acid testing) would allow us to deliver more safety products.
BACKGROUND AND AIM: Using of safety blood products did not stop improving these last years. The use of effective methods as well immunologicals as virologicals ones really reduces risk associated to blood transfusion. However, it persists residual risk (RR) of transfusion transmitted viral diseases. The aim of our study was to detect cases of seroconversion for HIV,and HBV among donors in the Senegalese national blood bank. And then, we estimated the RR of these virus. METHODS: We led a transverse retrospective study from 2003 (January 1st) to 2005 (December 31st). Had been included donors with at least two donations of blood during the period of study. They had to be seronegative for HIV and HBV after the first donation. All donors with only one donation had been excluded. RR was estimated by multiplying incidence rates by the durations of the window periods. RESULTS: During 3 years, we collected 425,503 donations; 388 were positive for HIV and 4240 for HBV. But we noted only two cases of seroconversion for HIV and 23 for HBV. So, RR estimated was 3,5 in 100,000 donation for HIV and 102,45 in 100,000 donations for VHB. CONCLUSION: It emerges from this study that the risk of blood transmitted virus is always high. Introduction of more sensitive tests (as nucleic acid testing) would allow us to deliver more safety products.
Authors: Jean Jacques N Noubiap; Jobert Richie N Nansseu; Shalom Tchokfe Ndoula; Jean Joel R Bigna; Ahmadou M Jingi; Joël Fokom-Domgue Journal: BMC Public Health Date: 2015-05-02 Impact factor: 3.295
Authors: B F Faye; D Sow; M Seck; N Dieng; S A Toure; M Gadji; A B Senghor; Y B Gueye; D Sy; A Sall; T N Dieye; A O Toure; S Diop Journal: Adv Hematol Date: 2017-05-11
Authors: Angelita Silva de Miranda Corrêa; Letícia Martins Lamarão; Priscilla Cristina Moura Vieira; Renata Bezerra Hermes de Castro; Núbia Caroline Costa de Almeida; Jairo Augusto Américo de Castro; Maria Salete Maciel de Lima; Mauricio Koury Palmeira; Ana Luiza Langanke Pedroso Meireles; Rommel Rodríguez Burbano Journal: PLoS One Date: 2018-12-19 Impact factor: 3.240
Authors: Alexandra Ducancelle; Pierre Abgueguen; Jacques Birguel; Wael Mansour; Adeline Pivert; Hélène Le Guillou-Guillemette; Jean-Jacques Sobnangou; Amélie Rameau; Jean-Marie Huraux; Françoise Lunel-Fabiani Journal: PLoS One Date: 2013-11-12 Impact factor: 3.240
Authors: Benjamin Seri; Albert Minga; Delphine Gabillard; Bamori Dembele; Seidou Konate; Jérôme Le Carrou; Lambert Dohoun; Yao Abo; Sophie Karcher; Patrick Coffie; Thérèse N'Dri-Yoman; Alain Attia; Serge P Eholié; Christine Danel; Karine Lacombe; Xavier Anglaret; Anders Boyd Journal: Open Forum Infect Dis Date: 2018-03-16 Impact factor: 3.835
Authors: Théophile Mitima Kashosi; John Kivukuto Mutendela; David Lupande Mwenebitu; Jeff Kabinda Maotela; Kanigula Mubagwa Journal: Pan Afr Med J Date: 2018-07-04